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Private health care in South Africa is largely funded by 
medical schemes that derive their funds from contributions 
by members of the public and/or their employers. In 2004 
contributions to medical schemes amounted to R51.3 billion.1 
Medical specialists accounted for 16% (R8.21 billion) of the 
annual distribution of this sum and pathology laboratories 
were estimated to account for 28% of payments to medical 
specialists (R2.30 billion or 4.5% of total contributions). 
In the search for better management of health care 
expenditure it is not surprising that health care administrators 
are also focusing on laboratory expenditure. This focus is 
not unique to South Africa and concern over inappropriate 
laboratory test utilisation has been expressed elsewhere.2,3 The 
magnitude of excessive test utilisation has been estimated by 
some authors4,5 to range between 20% and 95% of tests ordered, 
with a pathologist in one article6 estimating that 26.5% of tests 
were excessive. Apart from the economic impact on patients 
and medical schemes, there is legitimate concern about the 
detrimental clinical impact of over-investigation resulting in 
the Ulysses syndrome.7 
A review of the literature failed to reveal any published 
articles on the utilisation of laboratory procedures in South 
Africa. This study was undertaken to assess the patterns of 
test utilisation in the private health care sector where a fee-for-
service reimbursement model is in place. 
Methods
Accounts submitted with electronic data interface from 
pathology laboratories to a medical scheme for payment, 
were collected for a 3-year period between January 2003 and 
December 2005.  Each line represented a claim for a procedure 
(laboratory test) as defined in the National Health Reference 
Price List (NHRPL) as published by the Board of Healthcare 
Funders and subsequently the Council for Medical Schemes. 
Each line contained information on the beneficiary (unique 
number only), referring medical practitioner (practice number), 
pathology laboratory (practice number), service date, account 
number, laboratory number, NHRPL code, description of the 
procedure, price of the procedure and location of the patient (in 
hospital v. out of hospital). 
Duplicate claims and claims where information was 
incomplete were excluded from further analysis. Pathology 
laboratories that were not in operation for at least 90% of the 
duration of the study were excluded as well as a number of 
small laboratories (less than 1% market share individually) or 
laboratories that did not provide a service in all the disciplines 
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Objective. To analyse the patterns of pathology procedures 
performed in the private pathology sector in South Africa. 
To determine what the differences between the individual 
practices are and to attempt to explain any differences.
Design. A retrospective analysis of claims from pathology 
laboratories submitted by electronic interface to a medical aid 
administrator between January 2003 up to December 2005 
were analysed. The data were sorted according to the practice 
number of the pathology laboratory and referring doctor, 
account number, laboratory number, beneficiary number and 
the origin of the claim (in hospital or out of hospital). The 
number of claims for every procedure was compared across 
different laboratories.
Results. Sufficient data were available on 5.4 million claim lines 
over the 3-year period (92% of the total lines submitted over 
the period). The total amount claimed increased by 2.5% and 
9.9%, the number of test procedures increased by 1.4% and 
17.7%, and the number of accounts increased by 4.8% and 0.9% 
in 2004 and 2005 respectively. These increases occurred despite 
a decrease in active beneficiaries of 1.6% and 4.0% in 2004 and 
2005.  The average cost per active beneficiary per month varied 
between R494 and R611 in 2005. A relatively few common test 
procedures (30) contributed disproportionately to the total 
number of procedures (67.8%) and cost (56.9%) of laboratory 
testing. The utilisation of individual procedures varied 
between laboratories with large differences in the performance 
of common tests such as erythrocyte sedimentation rate, 
reticulocyte count, protein electrophoresis and creatinine.
Conclusion. The differences in the cost of pathology claims 
between individual laboratories were larger than expected. 
There was evidence of inappropriate test utilisation. Part 
of the differences between laboratories under control of the 
laboratories and are a result of request form design, test profile 
content and reflexing of tests. 
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of clinical pathology (histopathology- or cytology-only 
laboratories). 
Descriptive statistics were calculated for each individual 
laboratory to express the cost per episode. An episode was 
defined as all the procedures on an account and could consist 
of multiple laboratory numbers (specimens) over a period 
of time. An alternative definition of an episode is all the 
procedures on a beneficiary  (patient) in a calendar month. 
These beneficiaries are subsequently called ‘active beneficiaries’ 
in this document. The frequency of individual test procedure 
utilisation was established on the data from 2005 as nonspecific 
technology-related codes were commonly utilised for C-
reactive protein and haemoglobin A1c before 2005. The most 
common test procedures were identified and utilisation 
patterns for the individual laboratories for these specific 
procedures were further analysed. 
Results
Sufficient data were available on 5 434 709 claim lines over the 
3-year period (92% of the total number of lines submitted over 
the period). This represented 826 811 accounts and 580 277 
active beneficiaries. The data originated from 6 pathology 
laboratories as identified by the unique practice numbers on 
the accounts. The laboratories are identified as A - F in the text, 
tables and figures. 
The total amount claimed by the laboratories increased 
by 2.5% and 9.9% over the preceding year in 2004 and 
2005 respectively. Over the same period the number of test 
procedures increased by 1.4% and 17.7% respectively, while the 
number of accounts increased by 4.8% and 0.9% respectively. 
These increases occurred despite a decrease in the number of 
active beneficiaries of 1.6% and 4.0% in 2004 and 2005.  
The cost and number of test procedures per episode are 
given in Table I and Fig. 1. Between 2004 and 2005 the average 
cost of a test procedure declined by 6.6%, but the number 
of test procedures per active beneficiary increased by 22.7%, 
with the result that the cost per active beneficiary increased by 
14.5%. 
Laboratories C, D and E followed a pattern of decreased 
average cost per test procedure, but with more test procedures 
per active beneficiary (and per account) resulting in an 
increased cost per active beneficiary. Laboratories A and B 
revealed a contrary trend, with an increased average cost 
per test procedure and a small increase (laboratory A) or 
decrease (laboratory B) in the number of test procedures but 
with a similar trend in the average cost per active beneficiary. 
Laboratory F was the only laboratory that showed a decrease 
in average cost per active beneficiary in 2005. Laboratory F 
stopped trading as a separate entity towards the end of 2005. 
The range of the average cost per test procedure increased from 
R6.39 in 2003 to R28.67 in 2005. This increase in range reflects 
the opposing trends of decreasing and increasing average test 
costs. From Fig. 1 it is apparent that in laboratories E and F this 
occurred abruptly in September 2004, while in laboratories C 
and D a change occurred in June 2005. 
The cost per active beneficiary per month ranged between 
R494.21 and R611.55 in 2005, with a difference of R117.34. The 
maximum difference in 2004 was R139.54, while in 2003 it was 
R112.40. Laboratory C consistently provided the lowest cost per 
active beneficiary over the period.
The relative frequency with which individual procedures 
were performed is represented in Table II. A total of 643 
NHRPL procedure codes are potentially available for billing 
pathology procedures. The 10 most frequently requested tests 
represented 36.3% of all tests and contributed to 27.4% of all 
pathology expenditure. The corresponding figures for the 
top 30 tests are 67.8% and 56.8% respectively. The top 50 tests 
represented 81.5% of all procedures and 73.6% of pathology 
expenditure (data not shown). The tests represented in Table II 
are common, low-complexity procedures that are performed in 
bulk, mostly on automated laboratory instruments. 
Fig. 1. Comparison between laboratories with regard to: (a) average cost 
of test procedures; (b) average cost of accounts; and (c) average cost per 
beneficiary who underwent pathology procedures in a calendar month.
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Table I. Cost and activity parameters for laboratories in 2003, 2004 and 2005 (%2004 indicates the percentage difference with 
2003 as a baseline, %2005 indicates the percentage difference with 2004 as a baseline) 
 2003 2004 2005 %2004 %2005
Average cost/test
Lab A  R56.18  R60.53  R63.41 7.7 4.8
Lab B  R55.13  R56.41  R70.36 2.3 24.7
Lab C  R58.86  R59.21  R46.59 0.6 -21.3
Lab D  R53.51  R53.84  R41.69 0.6 -22.6
Lab E  R59.90  R52.29  R45.72 -12.7 -12.6
Lab F  R54.87  R52.02  R45.40 -5.2 -12.7
Combined  R56.62  R57.22  R53.43 1.1 -6.6
Average cost/account
Lab A  R378.91  R391.68  R426.88 3.4 9.0
Lab B  R330.19  R336.68  R399.19 2.0 18.6
Lab C  R300.78  R285.72  R321.36 -5.0 12.5
Lab D  R310.11  R328.32  R360.29 5.9 9.7
Lab E  R397.94  R355.16  R383.46 -10.8 8.0
Lab F  R440.32  R373.66  R348.29 -15.1 -6.8
Combined  R360.19  R352.31  R383.90 -3.3 8.5
Average number of tests/account
Lab A 6.7 6.5 6.7 -4.1 4.0
Lab B 6.0 6.0 5.7 -0.4 -4.9
Lab C 5.1 4.8 6.9 -5.6 42.9
Lab D 5.8 6.1 8.6 5.2 41.7
Lab E 6.6 6.8 8.4 2.2 23.5
Lab F 8.0 7.2 7.7 -10.5 6.8
Combined 6.4 6.2 7.2 -2.2 19.0
Average cost/active beneficiary/month
Lab A  R495.68  R521.17  R611.55 5.1 17.3
Lab B  R428.01  R438.48  R523.46 2.4 19.4
Lab C  R398.24  R429.47  R494.21 7.8 15.1
Lab D  R510.64  R569.01  R608.32 11.4 6.9
Lab E  R508.16  R491.74  R591.30 -3.2 20.2
Lab F  R558.11  R560.03  R549.47 0.3 -1.9
Combined  R480.97  R500.93  R573.79 4.1 14.5
Average number of tests/active beneficiary/month
Lab A 8.82 8.61 9.64 -2.4 12.0
Lab B 7.76 7.77 7.44 0.1 -4.2
Lab C 6.77 7.25 10.61 7.1 46.3
Lab D 9.54 10.57 14.59 10.8 38.0
Lab E 8.48 9.4 12.93 10.8 37.6
Lab F 10.17 10.77 12.10 5.9 12.3
Combined 8.50 8.75 10.74 2.9 22.7
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The utilisation of individual procedures and the relative 
frequency of certain procedures varied between laboratories.  
The details of selected test procedures are presented here.
1. Erythrocyte sedimentation rate (ESR) is a common 
laboratory procedure used as a nonspecific marker of an 
inflammatory response. Laboratory D performed relatively 
more ESR procedures relative to full blood counts (FBCs) 
than any other laboratory by a considerable margin (Fig. 2a). 
Even if laboratory D is ignored, the range of ESR to FBC in 
all patients varied between laboratories by 33 - 51.8%. All 
laboratories except laboratory D had a higher ratio of ESR/
FBC in outpatients than in hospitalised patients. Laboratory 
D performed ESR on 73.7% of FBCs on hospitalised patients, 
while laboratories C and E performed the procedure in 22.5% 
and 22.7% of cases respectively. 
2. Reticulocyte count is a useful procedure to assess bone 
marrow response in anaemic patients. On average laboratory 
C consistently performed a reticulocyte count in 0.4% of FBCs 
(Fig. 2b). Laboratory E performed this procedure in 7.9% of 
FBCs.  Laboratory F increased the frequency of this procedure 
abruptly in July 2004. Laboratory D reduced the frequency of 
this procedure in a similar fashion in August 2004.
3.  Protein electrophoresis is regarded in some circles in 
South Africa as part of a ‘liver function profile’. As liver 
function tests (LFTs) are not identifiable with a unique NHRPL 
code, gamma glutamyl transferase (GGT) is used as a surrogate 
marker of LFT. Other components of a LFT include albumin, 
total protein, aspartate transaminase, alanine transaminase, 
lactate dehydrogenase, alkaline phosphatase, total and 
conjugated bilirubin (all of which are in the top 30 tests). Serum 
protein electrophoresis is an invaluable tool in diagnosing 
and monitoring of monoclonal bands in myeloproliferative 
diseases and as such is a test that can be expected to occur 
mainly in people older than 50 years. However routine 
screening for monoclonal bands with protein electrophoresis is 
not recommended and routine testing in young people has no 
place.
On average laboratories A, C, D and F performed protein 
electrophoresis in 8.7% of all cases where a GGT (LFT) 
was performed (Fig. 3a). On average laboratories B and 
Table II. The 30 most frequently performed pathology procedures in 2005 
          Cumulative frequency       Cumulative monetary 
NHRPL code* Procedure description       of the procedures (%)  value of the procedures (%)
3797  Platelet count        5.56     1.42
3755  Full blood count      11.00     7.91
4032  Creatinine     15.85     9.90
4171  Sodium + potassium + chloride + CO2 + urea  20.32   17.96
4057  Glucose: quantitative    24.57   19.70
3805  Prothrombin index     27.14   21.45
3743  Erythrocyte sedimentation rate   29.65   22.30
3999  Albumin      32.04   23.61
3947  C-reactive protein     34.18   26.19
4130  Aspartate aminotransferase (AST)   36.30   27.49
4050  Glucose strip-test with photometric reading  38.38   27.91
4131  Alanine aminotransferase (ALT)   40.38   29.14
4134  Gamma glutamyl transferase (GGT)   42.35   30.35
4001  Alkaline phosphatase    44.22   31.45
4133  Lactate dehydrogenase (LD)    46.09   32.60
4117  Protein: total     47.77   33.19
4009  Bilirubin: total     49.42   34.09
3867  Miscellaneous microscopy (body fluids, urine, etc.) 51.07   35.01
4076  Blood gas and ancillary tests – max 6/patient/day  52.71   38.59
4025  Cholesterol/HDL/LDL/triglycerides   54.33   43.56
4010  Bilirubin: conjugated    55.94   44.22
4507  Thyrotropin (TSH)     57.38   47.43
3893  Bacteriological culture: miscellaneous   58.73   48.40
3806  Therapeutic drug level: dosage   60.04   49.07
3762  Haemoglobin estimation    61.29   49.33
4113  Potassium     62.54   49.84
4519  Prostate-specific antigen    63.70   51.76
4094  Magnesium: spectrophotometric   64.78   52.20
4017  Calcium: spectrophotometric    65.85   52.63
4484  Thyrotropin (TSH) + free thyroxine (FT4)  67.81   56.87
*NHRPL code is the code allocated to the procedure in the National Health Reference Price List.
HDL = high-density lipoprotein; LDL = low-density lipoprotein.
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E performed the same procedure in 26.8% and 26.5% of 
instances. In hospitalised patients, laboratory B performed 
protein electrophoresis in 55.9% of instances where a GGT was 
performed during 2003 and this was reduced to 27.9% in 2005 
(data not shown).
The laboratories with the highest incidence of protein 
electrophoresis (B and E) had the lowest percentage of patients 
older than 50 years (68.9% and 74.8% respectively, Fig. 3b). 
Conversely the laboratory with the lowest incidence (7.6%) of 
protein electrophoresis per GGT (laboratory C) had the highest 
percentage of patients over 50 years (92.8%). 
4. Urea and electrolytes is a profile identifiable by a single 
NHRPL code and is one of the few instances where the cost of 
the profile is less than the sum of the components. Creatinine 
may be more valuable than urea as a marker of renal function. 
Creatinine was performed with a urea and electrolyte profile in 
98.8% of all laboratories except laboratory D which performed 
this combination in approximately 74.9% of instances.
5. Laboratory A maintained a constant percentage of 
approximately 50% glucose tests compared with cholesterol 
tests in hospitalised patients for the entire period (Fig. 4). 
Laboratory C exhibited a dramatic increase during 2003, which 
continued unabated in 2004 (3.4-fold from the baseline), and 
ended 2005 with a 4.5-fold increase over the baseline of early 
2003.
Discussion 
A potential limitation of this study is that the claims 
received by the medical scheme administrator may not be a 
representative sample of the total medical aid industry in South 
Africa. Differences in pathology claims to medical schemes 
may arise from a number of factors such as geographical 
distribution, demographic profile, socio-economic profile, 
disease exposure of members and benefit design of a medical 
scheme. Despite this limitation we are of the opinion that 
the results merit consideration and that the results are an 
indication of the practice of pathology laboratories in South 
Africa. As no published results on the topic of laboratory test 
Fig. 2. Comparison of tests related to full blood counts: (a) erythrocyte 
sedimentation rate (or viscosity) ratio to full blood counts; and (b) reticulo-
cyte ratio to full blood counts.
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Fig. 3. Variation in the performance of protein electrophoresis: (a) com-
parison between laboratories with regard to the ratio of serum protein 
electrophoresis to gamma glutamyl transferase; (b) comparison between 
laboratories of serum protein electrophoresis per age band of patients in 
years.
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Fig. 4. Comparison between laboratories with regard to the ratio of glucose 
procedures to serum cholesterol in hospitalised patients.
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utilisation in South Africa are available, this article may serve 
as a departure point for discussion and future research. 
Part of the difficulty in a study such as this one is to decide 
what performance parameters to use. A submitted claim line 
represents a single test procedure with a specific NHRPL code 
and the average cost per procedure could in theory provide a 
means of comparing different laboratories. When the mixture 
of tests performed by a laboratory changes abruptly, as with 
the increase in glucose tests discussed above, this parameter 
is useful in identifying these events provided that the cost of 
the procedure is different from the average and the volumes 
are sufficient to influence the average.  In the medical scheme 
environment it is customary to express events or costs as the 
average for the total number of members (insured families) or 
total number of beneficiaries. In comparing the performance of 
laboratories this would only make sense if market share were 
equally distributed among service providers.
Cost per account provides an alternative way of comparing 
the performance of pathology laboratories. Differences in the 
way specimens are handled (laboratory numbers allocated to 
each department, separate laboratory numbers at branches, 
etc.) and the period that an account remains active can 
influence the composition of an account. Monitoring at account 
level is especially valid within a laboratory over time, but 
less so across laboratories. The same argument holds for the 
number of lines (tests) per account as a measure of testing 
activity. From the data in Table I and Fig. 1 it appears that 
laboratories C and D had the lowest cost per line and cost 
per account, but despite this laboratory D had the second 
highest cost per active beneficiary in 2005. The cost per active 
beneficiary cannot be predicted from line or account level 
comparisons in this instance. Measuring costs and events 
at the level of an active beneficiary is preferred and it is 
recommended that this parameter be used for future studies. 
This allows comparison between laboratories by measuring 
performance on actual patient referrals. By specifying the 
period as a calendar month it is inevitable that some active 
members will be counted twice in consecutive months if the 
event occurs over a month end and beginning. However 
this would affect all laboratories equally and would allow 
monitoring during a calendar year.
The 9.9% increase in monetary value for claims received for 
2005 was surprising taking into consideration that the number 
of active beneficiaries decreased by 4.0% over the period. 
The resultant 14.5% increase in cost per active beneficiary 
per month cannot be explained by the general NHRPL tariff 
increase of 5.2% that was granted for 2005. The only alternative 
explanation for the increases is an increase in test utilisation, 
and this is confirmed by the increase in average number of 
tests per account and active beneficiary.
The lower-cost laboratories B and C are located in coastal 
regions, while laboratories A and D are located in the interior. 
Variation in laboratory practice can be geographical and may 
represent differences in disease incidence, teaching habits and 
local custom. However there is not a convincing scientific 
rationale for the geographical differences observed in this 
study.
The 30 most commonly requested tests represent 4.7% of 
available NHRPL codes but 67.8% of procedures and 56.9% of 
pathology expenditure. Efforts to address laboratory utilisation 
should focus firstly on these common tests and for this 
reason the variation of selected tests from the top 30 list was 
further investigated. The very high incidence of ESR per FBC 
and almost universal creatinine with ‘urea and electrolytes’ 
is a cause of concern, and efforts to decrease excessive and 
inappropriate utilisation of these specific tests have been 
described elsewhere in the literature.8 The fact that laboratory 
D consistently performed creatinine in only 74.9% of cases 
compared with all other laboratories that performed these 
procedures in combination in more than 98% of cases would 
suggest that significant over- or under-utilisation occurs. The 
same can be said for the high ESR incidence at laboratory 
D compared with the other laboratories. The reason for the 
differences can be attributed at least in part to the design of 
the pathology request form, with most laboratories except 
laboratory D not offering the option to order a ‘urea and 
electrolytes’ without creatinine. On examining a sample of 
request forms it would appear almost impossible to order the 
individual components of ‘electrolytes’. 
On average, laboratory C performed reticulocyte counts 
with 0.4% of FBCs. When compared with the almost 20-
fold higher percentage (7.9%) of laboratory E, there is no 
ready explanation. The sudden increase in reticulocyte 
performance by laboratory F occurred in the same time period 
as the acquisition by laboratory E. The drop in reticulocyte 
performance a month later by laboratory D followed a meeting 
with the management of the laboratory where this specific 
issue was discussed. Reticulocyte performance is under control 
of the laboratory as the test is reflexed based on a haemoglobin 
value, often without consultation or consent of the referring 
clinician.
The high incidence of serum protein electrophoresis in 
laboratories E and B contrasts sharply with laboratory C. 
The age distribution of patients who had a serum protein 
electrophoresis by the individual laboratories is compatible 
with an appropriate utilisation of this procedure by laboratory 
C. The marked increases in glucose utilisation can be attributed 
to the implementation of a point-of-care testing device in 
a hospital group that was reported to own a stake in the 
particular laboratories. 
The variations observed can be at least partly explained 
by factors under control of the individual laboratories such 
as the design of the pathology request form, the expanding 
content of profiles and the reflexing of tests such as reticulocyte 
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counts. Other contributing factors may include the existence of 
business opportunities that arise from a corporate shareholder, 
as seen with the selective increase in glucose performance 
above. 
There is therefore clear evidence that differences in the 
utilisation of laboratory tests occur in the South African private 
health care sector. In the absence of scientifically defendable 
differences in disease distribution the differences are likely to 
be secondary to inappropriate test utilisation. Inappropriate 
test utilisation can be due to over- or underutilisation of 
laboratory tests. The magnitude of this inappropriate utilisation 
was impossible to estimate with any degree of accuracy in this 
study as clinical information to judge clinical appropriateness 
of laboratory tests was not available. The compulsory 
submission of International Classification of Diseases (ICD10) 
codes as envisaged by the Council for Medical Schemes will be 
an invaluable tool for the rational assessment and management 
of laboratory test utilisation in future. 
By arbitrarily assuming that the lowest utilisation in each 
parameter examined above represents ideal utilisation, a 
potentially large amount of expenditure could be avoided. 
If the lowest-cost laboratory is accepted as ideal behaviour, 
a cost saving of 15% is potentially achievable. It is debatable 
whether the lowest utilisation in this sample represents ideal or 
acceptable test utilisation.  
The most effective way to improve test utilisation is to 
control the design of the pathology request form.2,3,8,9 It has 
been shown conclusively that the absence of ‘tick boxes’, 
limited profile content and individual requesting of tests 
reduces pathology expenditure without compromising 
patient care. From another perspective it can be said that 
if the intention was to increase pathology test utilisation, it 
would be difficult to ‘improve’ the current pathology request 
forms. The current situation can be rectified by applying the 
requirements applicable to pharmaceutical scripts to pathology 
request forms, i.e. unambiguous requesting of a single test 
by the referring doctor, with the requisition verified by his/
her signature, on a form that does not contain a suggestion 
list with multiple ‘tick boxes’ and exotic test profiles. This 
would bring South Africa in line with other countries such as 
Australia10 that have already resolved these issues. 
Consideration should be given to re-designing the format 
of the NHRPL pricing structure to eliminate incentives for 
overutilisation of laboratory tests. Currently each NHRPL 
tariff contains an element that can be described as an ‘episode 
fee’. This component contains elements such as the cost of 
consumables, the cost of the phlebotomist, couriers, and 
administrative and accounting services associated with 
performing the test, and is based on an assumption of the 
average number of test procedures per account. Table I shows 
that the trend is to increase the number of tests per account. 
Secondly, there is wide variation in the number of tests per 
account between different laboratories, with the consequence 
that laboratories with a high test per account ratio benefit 
relatively more.  By removing the episode fee component from 
each individual NHRPL item and substituting it with a single 
new NHRPL code for an episode fee, the temptation to increase 
the number of tests per event will be reduced. 
An additional change to the NHRPL that should be 
considered is to limit the content of profiles and to expand the 
concept of billing decay to all cases where multiple tests are 
performed on a single analyser platform. 
Conclusion
Considerable variation exists in the billing practices of South 
African pathology laboratories that can be attributed to 
factors not related to patient care. The extent of the excessive 
laboratory utilisation cannot be estimated accurately at present 
but is probably significant. Practical measures exist, that have 
been validated elsewhere, to improve laboratory test utilisation. 
The most important aspect to attend to is regulations to control 
pathology request forms and the content of test profiles.
   The contributions of Mr H J van Rensburg and Mr R McCallum 
of Veripath with database interrogation and discussion of the 
results are gratefully acknowledged.
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